Merck & Co., Inc. Share-based Payment Arrangement, Expense, after Tax
Merck & Co., Inc. (MRK) reported Share-based Payment Arrangement, Expense, after Tax of $103.00 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2021-05-05
- Merck & Co., Inc. share-based payment arrangement, expense, after tax for the quarter ending 2021-03-31 was $103.00M, a 10.75% increase year-over-year.
- Merck & Co., Inc. share-based payment arrangement, expense, after tax for the quarter ending 2020-09-30 was $109.00M, a 25.29% increase year-over-year.
- Merck & Co., Inc. share-based payment arrangement, expense, after tax for the quarter ending 2020-06-30 was $105.00M, a 9.38% increase year-over-year.
- Merck & Co., Inc. share-based payment arrangement, expense, after tax for the quarter ending 2020-03-31 was $93.00M, a 17.72% increase year-over-year.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 9 month |
|---|---|---|---|
| 2021-03-31 | $103.00M 10-Q · filed 2021-05-05 | ||
| 2020-09-30 | $109.00M 10-Q · filed 2020-11-05 | $214.00M derived: sum of 2 quarters · filed 2020-11-05 | $306.00M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $105.00M 10-Q · filed 2020-08-05 | $198.00M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $93.00M 10-Q · filed 2021-05-05 | ||
| 2019-09-30 | $87.00M 10-Q · filed 2020-11-05 | $183.00M derived: sum of 2 quarters · filed 2020-11-05 | $264.00M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $96.00M 10-Q · filed 2020-08-05 | $176.00M 10-Q · filed 2020-08-05 | |
| 2019-03-31 | $79.00M 10-Q · filed 2020-05-06 | ||
| 2018-09-30 | $77.00M 10-Q · filed 2019-11-05 | $154.00M derived: sum of 2 quarters · filed 2019-11-05 | $219.00M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $77.00M 10-Q · filed 2019-08-06 | $142.00M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $65.00M 10-Q · filed 2019-05-08 | ||
| 2017-09-30 | $53.00M 10-Q · filed 2018-11-06 | $110.00M derived: sum of 2 quarters · filed 2018-11-06 | $162.00M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $57.00M 10-Q · filed 2018-08-07 | $109.00M 10-Q · filed 2018-08-07 | |
| 2017-03-31 | $52.00M 10-Q · filed 2018-05-08 | ||
| 2016-09-30 | $53.00M 10-Q · filed 2017-11-07 | $108.00M derived: sum of 2 quarters · filed 2017-11-07 | $156.00M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $55.00M 10-Q · filed 2017-08-08 | $103.00M 10-Q · filed 2017-08-08 | |
| 2016-03-31 | $48.00M 10-Q · filed 2017-05-09 | ||
| 2015-09-30 | $52.00M 10-Q · filed 2016-11-07 | $109.00M derived: sum of 2 quarters · filed 2016-11-07 | $152.00M 10-Q · filed 2016-11-07 |
| 2015-06-30 | $57.00M 10-Q · filed 2016-08-08 | $101.00M 10-Q · filed 2016-08-08 | |
| 2015-03-31 | $44.00M 10-Q · filed 2016-05-09 | ||
| 2014-09-30 | $52.00M 10-Q · filed 2015-11-05 | $106.00M derived: sum of 2 quarters · filed 2015-11-05 | $145.00M 10-Q · filed 2015-11-05 |
| 2014-06-30 | $54.00M 10-Q · filed 2015-08-06 | $93.00M 10-Q · filed 2015-08-06 | |
| 2014-03-31 | $39.00M 10-Q · filed 2015-05-07 | ||
| 2013-09-30 | $47.00M 10-Q · filed 2014-11-10 | $99.00M derived: sum of 2 quarters · filed 2014-11-10 | $146.00M 10-Q · filed 2014-11-10 |
| 2013-06-30 | $52.00M 10-Q · filed 2014-08-07 | $99.00M 10-Q · filed 2014-08-07 | |
| 2013-03-31 | $47.00M 10-Q · filed 2014-05-08 | ||
| 2012-09-30 | $60.00M 10-Q · filed 2013-11-07 | $124.00M derived: sum of 2 quarters · filed 2013-11-07 | $176.00M 10-Q · filed 2013-11-07 |
| 2012-06-30 | $64.00M 10-Q · filed 2013-08-07 | $116.00M 10-Q · filed 2013-08-07 | |
| 2012-03-31 | $52.00M 10-Q · filed 2013-05-09 | ||
| 2011-09-30 | $56.00M 10-Q · filed 2012-11-09 | $126.00M derived: sum of 2 quarters · filed 2012-11-09 | $188.00M 10-Q · filed 2012-11-09 |
| 2011-06-30 | $70.00M 10-Q · filed 2012-08-07 | $131.00M 10-Q · filed 2012-08-07 | |
| 2011-03-31 | $61.00M 10-Q · filed 2012-05-08 | ||
| 2010-09-30 | $83.00M 10-Q · filed 2011-11-08 | $176.00M derived: sum of 2 quarters · filed 2011-11-08 | $264.00M 10-Q · filed 2011-11-08 |
| 2010-06-30 | $93.00M 10-Q · filed 2011-08-08 | $181.00M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |